CLINICAL_TRIALS
trial_result
· 2013-04-23
Clinical Trial Update: A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer [Phase 2]
Summary
Phase 2 trial of Trastuzumab-Mcc-DM1 in HER2-positive metastatic breast cancer completed with results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-04-23